Novovax’s Covovax gets emergency use authorization for children aged between 12-18 years


On Tuesday, Novovax announced that its COVID-19 vaccine has got emergency-use authorization from the Drugs Controller General of India (DCGI)  for adolescents falling between the age group of 12-18 years in India. The official statement released by Novovax, also known as NVX-CoV2373 reported that the vaccine is being manufactured and marketed in India by the Serum Institute of India (SII).  In India, the vaccine will be marketed under the brand name ‘Covovax’.  

The CEO of Serum Institute of India (SII), Adar Poonawala tweeted, “Novavax in global trials has demonstrated more than 90 percent efficacy. Serum Institute of India’s brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly. ” 

Last month after the last stage of trial testing, Novovax announced that its vaccine was 80% effective against Covid-19, it produced an immune response during the testing period, in which 460 Indian adolescents were innvolved. Novovax is also the first protein-based vaccine authorized for use in the age group of 12-18 years in India. 

Covovax is the fourth vaccine that got authorization for usage among adolescents who are 12 years of age or older. The other vaccines that got approval to help fight against Coronavirus are Biological E’s Corbevax, Zydus Cadila’s ZyCov-D, and Bharat Biotech’s Covaxin. The Covovax has also received an Emergency Use Listing (EUL) from the World Health Organization (WHO). 

In a statement President and Chief Executive Officer (CEO) of Novovax, Stanley C Erck said, “We’re proud of this first approval in adolescents given the efficacy and safety that our data show in this population and that our COVID-19 vaccine will provide an alternative protein-based vaccine option for individuals 12 years of age and older in India.”

According to the data by the health ministry of India,  till now a total of 50,32,055 first doses have been given to children aged between 12-14 years. 

Continue Reading on The India Saga.

Leave a Reply